Uterine fibroids and evidence-based medicine - Not an oxymoron

New England Journal of Medicine

Volumn 366, Issue 5, 2012, Pages 471-473

  Stewart, Elizabeth A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; IRON; LEUPRORELIN; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; ULIPRISTAL;

AMENORRHEA; ANEMIA; BONE TURNOVER; DRUG SAFETY; EDITORIAL; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; EVIDENCE BASED MEDICINE; HOT FLUSH; HUMAN; HYSTERECTOMY; IRON THERAPY; MENSTRUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; ULTRASOUND SURGERY; UTERUS MYOMA;

EID: 84856562883     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1114043     Document Type: Editorial

References (15)

1. Gliklich RE, Leavy MB, Velentgas P, et al. Identification of future research needs in the comparative management of uterine fibroid disease: a report on the priority-setting process, preliminary data analysis, and research plan. Rockville, MD: Agency for Healthcare Research and Quality, March 2011 (http://www.effectivehealthcare.ahrq.gov/ehc/products/152/642/ DEcIDE31-UterineFibroid-03-07-2011.pdf).
2. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005;308:1589-92. (Pubitemid 40807499)
3. Stewart EA. Uterine fibroids: the complete guide. Baltimore: Johns Hopkins University Press, 2007.
4. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-33. (Pubitemid 40800387)
5. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36. (Pubitemid 351620347)
6. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008; 112:1029-36.
7. Hodgen GD. Antiprogestins: the political chemistry of RU486. Fertil Steril 1991;56:394-5.
8. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20.
9. Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366:421-32.
10. Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Obstet Gynecol 1995;86:65-71.
11. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591-8. (Pubitemid 351589653)
12. Taran FA, Brown HL, Stewart EA. Racial diversity in uterine leiomyoma clinical studies. Fertil Steril 2010;94:1500-3.
13. Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;356:360-70. (Pubitemid 46148778)
14. Stewart EA, Rabinovici J, Tempany CM, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006;85:22-9. (Pubitemid 43063413)
15. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 2008;14(1):CR24-CR31.